title: VAMP followed by high dose melphalan and autologous bone marrow transplantation for multiple myeloma.
abstract: Fifty previously untreated patients with myeloma were entered into a 2-phase treatment programme: vincristine, adriamycin and methyl prednisolone (VAMP) followed by high dose intravenous melphalan (HDM) with autologous bone marrow transplantation where possible. The complete remission rate of 50% was associated with very good quality of life and the reversal of humoral immunosuppression. Complete remission is important in younger patients with myeloma as it represents a first step in achieving long, symptom- free survival.
authors.affiliation: Royal Marsden Hospital, London, UK.
authors.forename: T J
authors.initials: TJ
authors.lastname: McElwain
authors.forename: M E
authors.initials: ME
authors.lastname: Gore
authors.forename: M
authors.initials: M
authors.lastname: Meldrum
authors.forename: C
authors.initials: C
authors.lastname: Viner
authors.forename: I R
authors.initials: IR
authors.lastname: Judson
authors.forename: J S
authors.initials: JS
authors.lastname: Malpas
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016026:Bone Marrow Transplantation; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008297:Male; D008558:Melphalan / Q000008:administration & dosage; D008775:Methylprednisolone / Q000008:administration & dosage; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000601:surgery; D014182:Transplantation, Autologous; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D014750:Vincristine; D004317:Doxorubicin; D008558:Melphalan; D008775:Methylprednisolone